Eli Lily to acquire ImClone Systems Inc.

Oct. 6, 2008 at 3:58 PM

INDIANAPOLIS, Oct. 6 (UPI) -- Eli Lilly and Co. said Monday it had reached an agreement to purchase New York's ImClone Systems Inc., a leading cancer-drug company, for $6.5 billion.

The $70 per share offer is a 51 percent premium above ImClone's closing stock price on July 30, the company said in a statement.

"This strategic combination will create one of the leading oncology franchises in the biopharmaceutical industry," the statement said.

ImClone's Chief Executive Officer John Johnson said the company was "excited about the possibilities of improving outcomes for for individual patients and building value for shareholders."

The combined arsenal of cancer treatments allows the merged company to "target a broader array of solid tumor types including lung, breast, ovarian, colorectal, head and neck, and pancreatic," the statement said.

Both company boards have approved of the deal, which trumps a previous offer from Bristol-Myers Squibb, which offered ImClone $62 a share for the company, the Indianapolis Star reported.

Related UPI Stories
Topics: John Johnson
Latest Headlines
Trending Stories
Ted Cruz campaign pulls ad featuring softcore porn actress
Report: Clinton Foundation subpoenaed by State Dept. watchdog over charity projects
Ruby Rose, Gigi Hadid react to Kanye West's lyric about Taylor Swift
Kristen Wiig impersonates Peyton Manning on 'The Tonight Show'
NYC police officer found guilty of manslaughter in Brooklyn stairway shooting